Endodiag

What Endodiag does

Endodiag SAS is a French privately-held biotechnology company founded in 2011 by Cécile Réal, headquartered in Evry with an operational office in Paris. The company is focused exclusively on endometriosis, a disease affecting approximately 180 million women worldwide (10% of reproductive-age women) where average diagnostic delay is 7–11 years and the current gold standard is surgical laparoscopy. Endodiag's product portfolio comprises three integrated assets: EndoDTect®, a non-invasive blood test based on disease-specific biomarkers intended for early detection (currently in clinical validation); EndoGram®, a 10-biomarker biopsy-based test using a proprietary algorithm to generate disease recurrence risk scores that guide treatment and fertility strategy decisions; and EndoBiobank®, a regulatory-compliant biobank of more than 1,000 annotated human biological samples that is also made available to pharmaceutical and academic teams for drug target assessment and drug candidate evaluation.

The business model is B2B, targeting gynecologists, surgeons, and fertility specialists through direct clinical engagement and an established international network of expert KOLs. Revenue mechanics are tied to future commercialization of EndoDTect and EndoGram diagnostic services (modeled as one-time license per test in the data), with EndoBiobank positioned to support a parallel pharma-services revenue stream. To date, the company has raised approximately €5 million across two rounds (€750K seed in April 2012 from private investors and ~$4.57M in July 2017 from BNP Paribas Développement and Crédit Mutuel Equity) and remains pre-commercial, with 1-10 employees and validation-stage products.

Name

Endodiag

Legal name

Endodiag SAS

Website

https://endodiag.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Endodiag is a French biotech developing biomarker-based diagnostic tests for endometriosis, including a non-invasive blood test (EndoDTect), a biopsy-based prognostic test (EndoGram), and a regulated biobank (EndoBiobank), targeting gynecologists and fertility specialists.

Ownership category

akta.pro rank

Product category

Endometriosis Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industry

SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)

Keywords

• Endometriosis diagnostics
• Biomarker blood tests
• Gynecological diagnostics
• Women's health diagnostics
• Clinical biobank services

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic testing services: Endodiag generates revenue through the development and commercialization of diagnostic tests (EndoDTect® blood test and EndoGram® biopsy test) for endometriosis. These are intended for use by healthcare professionals to diagnose and guide treatment decisions for patients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Endodiag develops and commercializes proprietary biomarker-based diagnostic solutions for endometriosis intended for use by healthcare professionals. Its core offerings are EndoDTect®, a non-invasive blood test under validation for early disease detection; EndoGram®, a 10-biomarker biopsy-based prognostic test that provides disease recurrence risk scores to guide personalized treatment; and EndoBiobank®, a regulatory-compliant biobank used to support new therapy development and diagnostic validation studies.

Product overview

Endodiag is a diagnostic solutions company specializing in endometriosis. The company offers a portfolio of three integrated products: EndoDTect® is a non-invasive blood test using disease-specific biomarkers for early endometriosis detection; EndoGram® is a 10-biomarker biopsy test providing disease recurrence risk scores to guide treatment decisions; and EndoBiobank® is a regulatory-compliant biobank supporting drug discovery and development. Together, these products address the complete diagnostic and therapeutic guidance pathway from early detection to treatment optimization.

Differentiator

Problem solved

Functional benefit

Brands

• EndoDTect: A blood test for endometriosis detection based on biomarker analysis.
• EndoBiobank
• EndoGram

Products and services

• EndoDTect® A non-invasive blood test for endometriosis detection based on the analysis of disease-specific biomarkers. It analyzes changes in expression levels of biomarkers to indicate whether a subject has endometriosis, designed to combine high sensitivity and specificity and reduce the average 7–11 year diagnostic delay. Intended for healthcare professionals (gynecologists, surgeons).
• EndoGram® A 10-biomarker test based on analysis of biopsies taken during surgery. Uses a proprietary algorithm combining patient clinical factors to provide a disease recurrence risk score and biological profile to help physicians assess optimal therapeutic strategies and fertility planning.
• EndoBiobank® A regulatory-compliant biobank containing more than 1,000 human biological samples including fixed biopsies, serum, plasma, peritoneal fluid, primary cell cultures, and endometriosis-derived cell lines, annotated with patient clinical data. Used for assessment of new therapeutic targets and evaluation of new drug candidates, and as a resource for pharmaceutical and academic partners.
• Cell-based efficacy assays Apoptosis, proliferation, and migration assays developed using endometriosis-derived cells to support evaluation of potential efficacy of new drug candidates for pharmaceutical and academic partners.

Quantifiable outcome

• Diagnostic delay reduction from 7-11 years to potentially immediate through non-invasive blood testing
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• GenopolecoreStrategic or Co-development Partner · 1 January 2014Biotechnology cluster in Evry, France. Endodiag collaborates with Genopole for laboratory facilities and participates in joint science outreach events.
• Evry HospitalminorStrategic or Co-development Partner · 1 January 2014Collaboration with Evry's hospital for science outreach events and potentially for clinical research activities.
• Ashoka (Health IMPACT Program)coreStrategic or Co-development Partner · 1 January 2014Selected in Ashoka's Health IMPACT Program sponsored in partnership with Siemens Foundation. Endodiag won First Prize at Changemaker's Week in June 2014.
• Avenir Femmes SantéminorStrategic or Co-development Partner · 8 March 2013Launched first French Endometriosis Observatory in collaboration with Paris Université in March 2013.
• Paris UniversitéminorStrategic or Co-development Partner · 8 March 2013Academic collaboration for the first French Endometriosis Observatory, launched March 2013.
• Medical, academic and industrial teamscoreStrategic or Co-development PartnerEndodiag has partnerships with prestigious medical, academic and industrial teams around the world for drug development collaboration and diagnostic solution validation.
• Expert gynecologists (clinical network)coreStrategic or Co-development PartnerEstablished clinical network of international expert gynecologists for assessment of new drug targets and evaluation of diagnostic solutions.
• BePatientcoreStrategic or Co-development PartnerExpert in eHealth solutions, co-founded OZ2020 web community with Endodiag for endometriosis awareness and patient education.
• Patient associations (Endomind France, OZ2020)coreStrategic or Co-development PartnerPartnership with patient advocacy organizations for disease awareness campaigns, research fundraising (ENDOrun), and patient education initiatives.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Endodiag1

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endodiag